US20150376714A1 - Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer - Google Patents
Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer Download PDFInfo
- Publication number
- US20150376714A1 US20150376714A1 US14/765,294 US201414765294A US2015376714A1 US 20150376714 A1 US20150376714 A1 US 20150376714A1 US 201414765294 A US201414765294 A US 201414765294A US 2015376714 A1 US2015376714 A1 US 2015376714A1
- Authority
- US
- United States
- Prior art keywords
- benefit
- combined score
- taxane
- patient
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 229940123237 Taxane Drugs 0.000 title claims abstract description 61
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 56
- 230000008901 benefit Effects 0.000 title claims abstract description 52
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 29
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 29
- 238000009104 chemotherapy regimen Methods 0.000 title claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims abstract description 96
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- 101000821881 Homo sapiens Protein S100-P Proteins 0.000 claims abstract description 32
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 claims abstract description 25
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 claims abstract description 23
- 239000003550 marker Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 3
- 230000000306 recurrent effect Effects 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 12
- 238000002493 microarray Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000011227 neoadjuvant chemotherapy Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 30
- 230000004044 response Effects 0.000 description 29
- 102100021494 Protein S100-P Human genes 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 238000005259 measurement Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 229960001904 epirubicin Drugs 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940045799 anthracyclines and related substance Drugs 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000035572 chemosensitivity Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100135835 Homo sapiens PCSK6 gene Proteins 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 101150026420 S100P gene Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000012603 in vitro chemosensitivity assay Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 102100039864 ATPase family AAA domain-containing protein 2 Human genes 0.000 description 1
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100038387 Cystatin-SN Human genes 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 description 1
- 101710153170 Endothelial cell-specific molecule 1 Proteins 0.000 description 1
- 102000003965 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 102100033941 Ephrin-A5 Human genes 0.000 description 1
- 108010043939 Ephrin-A5 Proteins 0.000 description 1
- 102100039354 Epoxide hydrolase 4 Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100028953 Gelsolin Human genes 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 101000887284 Homo sapiens ATPase family AAA domain-containing protein 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000884768 Homo sapiens Cystatin-SN Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101000812405 Homo sapiens Epoxide hydrolase 4 Proteins 0.000 description 1
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
- 101000987094 Homo sapiens Moesin Proteins 0.000 description 1
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 240000004759 Inga spectabilis Species 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 101710153276 Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033501 Interleukin-32 Human genes 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150033052 MAS5 gene Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 102100027869 Moesin Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 101710180552 Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100028437 Versican core protein Human genes 0.000 description 1
- IZOBIZVXEKNCNN-ZNQIEUMMSA-N [(1r,2r,3's,4e,5s)-4-hexa-2,4-diynylidenespiro[3,6-dioxabicyclo[3.1.0]hexane-2,6'-oxane]-3'-yl] 3-methylbutanoate Chemical compound CC#CC#C\C=C([C@H]1O[C@H]11)\O[C@@]21CC[C@H](OC(=O)CC(C)C)CO2 IZOBIZVXEKNCNN-ZNQIEUMMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to methods, kits and systems for predicting the benefit from inclusion of taxane in a chemotherapy regimen based on the measurements of gene expression levels in tumor samples of breast cancer patients.
- breast cancer patients are frequently treated with radiotherapy, hormone therapy and cytotoxic chemotherapy to reduce the risk of recurrence.
- radiotherapy hormone therapy
- cytotoxic chemotherapy to reduce the risk of recurrence.
- anthracycline and taxane-based treatment strategies are commonly used in clinical routine, since these regimens have been shown to be superior compared to other standard chemotherapies.
- taxanes are among the most active agents, the absolute benefit of taxane-based treatment is modest (3-5%) and has to be balanced according to serious side-effects.
- Ki67 a well-known cell proliferation marker—has been described to predict the benefit from adjuvant taxane-based treatment in the PACS01 trial (Penault-Llorca, JCO, 2008). However, neither the association between Ki67 index and treatment effect nor any other clinicopathological parameter or biomarker predictive for the efficiency of taxanes has been validated so far.
- tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- cancer is not limited to any stage, grade, histomorphological feature, aggressivity, or malignancy of an affected tissue or cell aggregation.
- prediction relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (OAS, overall survival or DFS, disease free survival) of a patient, if the tumor is treated with a given therapy.
- a “benefit” from a given therapy is an improvement in health or wellbeing that can be observed in patients under said therapy, but isn't observed in patients not receiving this therapy.
- Non-limiting examples commonly used in oncology to gauge a benefit from therapy are survival, disease free survival, metastasis free survival, disappearance of metastasis, tumor regression, and tumor remission.
- a “risk” is understood to be a probability of a subject or a patient to develop or arrive at a certain disease outcome.
- the term “risk” in the context of the present invention is not meant to carry any positive or negative connotation with regard to a patient's wellbeing but merely refers to a probability or likelihood of an occurrence or development of a given condition.
- node positive means a patient having previously been diagnosed with lymph node metastasis. It shall encompass both draining lymph node, near lymph node, and distant lymph node metastasis. This previous diagnosis itself shall not form part of the inventive method. Rather it is a precondition for selecting patients whose samples may be used for one embodiment of the present invention. This previous diagnosis may have been arrived at by any suitable method known in the art, including, but not limited to lymph node removal and pathological analysis, biopsy analysis, in-vitro analysis of biomarkers indicative for metastasis, imaging methods (e.g. computed tomography, X-ray, magnetic resonance imaging, ultrasound), and intraoperative findings.
- imaging methods e.g. computed tomography, X-ray, magnetic resonance imaging, ultrasound
- biological sample is a sample which is derived from or has been in contact with a biological organism.
- biological samples are: cells, tissue, body fluids, lavage fluid, smear samples, biopsy specimens, blood, urine, saliva, sputum, plasma, serum, cell culture supernatant, and others.
- a “tumor sample” is a biological sample containing tumor cells, no matter if intact or degraded.
- mRNA is the transcribed product of a gene or a part of a gene and shall have the ordinary meaning understood by a person skilled in the art.
- a “molecule derived from an mRNA” is a molecule which is chemically or enzymatically obtained from an mRNA template, such as cDNA.
- expression level refers to a determined level of gene expression. This may be a determined level of gene expression as an absolute value or compared to a reference gene (e.g. a housekeeping gene) or to a computed average expression value (e.g. in DNA chip analysis) or to another informative gene without the use of a reference sample.
- the expression level of a gene may be measured directly, e.g. by obtaining a signal wherein the signal strength is correlated to the amount of mRNA transcripts of that gene or it may be obtained indirectly at a DNA or protein level, e.g. by immunohistochemistry, CISH, ELISA or RIA methods.
- the expression level may also be obtained by way of a competitive reaction to a reference sample.
- An expression value which is determined by measuring some physical parameter in an assay, e.g. fluorescence emission may be assigned a numerical value which may be used for further processing of information.
- a “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels.
- a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy individuals, diseased individuals, or diseased individuals having received a particular type of therapy, serving as a reference group.
- gene expressions values or combined scores consisting of a mathematical combination of one or more gene expression values, require to be compared to a “reference-value” to get a meaning in a clinical context.
- an expression value or a combined score exceeding such a “reference-value” may mean an improved or worsened likelihood of survival for a patient.
- Such “reference-value” can be a numerical cutoff value, it can be derived from a reference measurement of one or more other genes in the same sample, or one or more other genes and/or the same gene in one other sample or in a plurality of other samples. This is how “reference-value” within the meaning of this invention should be understood.
- An “algorithm” is a process that performs some sequence of operations to process an information.
- cytotoxic treatment refers to various treatment modalities affecting cell proliferation and/or survival.
- the treatment may include administration of alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, including monoclonal antibodies and kinase inhibitors.
- the cytotoxic treatment may relate to a treatment comprising microtubulestabilizing drugs such as taxanes or epothilones.
- neoadjuvant chemotherapy relates to a preoperative therapy regimen consisting of a panel of hormonal, chemotherapeutic and/or antibody agents, which is aimed to shrink the primary tumor, thereby rendering local therapy (surgery or radiotherapy) less destructive or more effective, enabling breast conserving surgery and evaluation of responsiveness of tumor sensitivity towards specific agents in vivo.
- a “microtubule stabilizing agent-based” treatment or therapy is a treatment or therapy comprising taxol or therapeutically effective derivatives thereof, epothilones or therapeutically effective derivatives thereof or other microtubule stabilizing cytotoxic drugs.
- taxane-based treatment or therapy is a treatment or therapy comprising taxol or therapeutically effective derivatives thereof.
- the principal mechanism of the taxane class of drugs is the disruption of microtubule function.
- hybridization-based method refers to methods imparting a process of combining complementary, single-stranded nucleic acids or nucleotide analogues into a single double stranded molecule. Nucleotides or nucleotide analogues will bind to their complement under normal conditions, so two perfectly complementary strands will bind to each other readily. In bioanalytics, very often labeled, single stranded probes are in order to find complementary target sequences. If such sequences exist in the sample, the probes will hybridize to said sequences which can then be detected due to the label. Other hybridization based methods comprise microarray and/or biochip methods.
- probes are immobilized on a solid phase, which is then exposed to a sample. If complementary nucleic acids exist in the sample, these will hybridize to the probes and can thus be detected.
- array based methods Yet another hybridization based method is PCR, which is described above. When it comes to the determination of expression levels, hybridization based methods may for example be used to determine the amount of mRNA for a given gene.
- An oligonucleotide capable of specifically binding sequences a gene or fragments thereof relates to an oligonucleotide which specifically hybridizes to a gene or gene product, such as the gene's mRNA or cDNA or to a fragment thereof. To specifically detect the gene or gene product, it is not necessary to detect the entire gene sequence. A fragment of about 20-150 bases will contain enough sequence specific information to allow specific hybridization.
- a PCR based method refers to methods comprising a polymerase chain reaction (PCR). This is a method of exponentially amplifying nucleic acids, e.g. DNA by enzymatic replication in vitro. As PCR is an in vitro technique, it can be performed without restrictions on the form of DNA, and it can be extensively modified to perform a wide array of genetic manipulations. When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers.
- PCR polymerase chain reaction
- PCR-based methods comprise e.g. real time PCR, and, particularly suited for the analysis of expression levels, kinetic or quantitative PCR (qPCR).
- qPCR kinetic or quantitative PCR
- Quantitative PCR refers to any type of a PCR method which allows the quantification of the template in a sample.
- Quantitative real-time PCR comprise different techniques of performance or product detection as for example the TaqMan technique or the LightCycler technique.
- the TaqMan technique for examples, uses a dual-labelled fluorogenic probe.
- the TaqMan real-time PCR measures accumulation of a product via the fluorophore during the exponential stages of the PCR, rather than at the end point as in conventional PCR.
- the exponential increase of the product is used to determine the threshold cycle, CT, i.e. the number of PCR cycles at which a significant exponential increase in fluorescence is detected, and which is directly correlated with the number of copies of DNA template present in the reaction.
- CT threshold cycle
- the set up of the reaction is very similar to a conventional PCR, but is carried out in a real-time thermal cycler that allows measurement of fluorescent molecules in the PCR tubes.
- a probe is added to the reaction, i.e., a single-stranded oligonucleotide complementary to a segment of 20-60 nucleotides within the DNA template and located between the two primers.
- a fluorescent reporter or fluorophore e.g., 6-carboxyfluorescein, acronym: FAM, or tetrachlorofluorescein, acronym: TET
- quencher e.g., tetramethylrhodamine, acronym: TAMRA, of dihydrocyclopyrroloindole tripeptide “minor groove binder”, acronym: MGB
- the 5′ to 3′ exonuclease activity of the Taq polymerase degrades that proportion of the probe that has annealed to the template (Hence its name: Taq polymerase+TacMan). Degradation of the probe releases the fluorophore from it and breaks the close proximity to the quencher, thus relieving the quenching effect and allowing fluorescence of the fluorophore. Hence, fluorescence detected in the real-time PCR thermal cycler is directly proportional to the fluorophore released and the amount of DNA template present in the PCR.
- array or “matrix” an arrangement of addressable locations or “addresses” on a device is meant.
- the locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats.
- the number of locations can range from several to at millions. Most importantly, each location represents a totally independent reaction site.
- Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays.
- a “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, nucleotide analogues, polynucleotides, polymers of nucleotide analogues, morpholinos or larger portions of genes.
- the nucleic acid and/or analogue on the array is preferably single stranded.
- Arrays wherein the probes are oligonucleotides are referred to as “oligo-nucleotide arrays” or “oligo-nucleotide chips.”
- a “microarray,” herein also refers to a “biochip” or “biological chip”, an array of regions having a density of discrete regions of at least about 100/cm2, and preferably at least about 1000/cm2.
- the term “therapy modality”, “therapy mode”, “regimen” or “chemo regimen” as well as “therapy regimen” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or immune stimulating, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermic, and/or hypothermia for cancer therapy.
- the administration of these can be performed in an adjuvant and/or neoadjuvant mode.
- the composition of such “protocol” may vary in the dose of the single agent, timeframe of application and frequency of administration within a defined therapy window.
- measurement at a protein level refers to methods which allow for the quantitative and/or qualitative determination of one or more proteins in a sample. These methods include, among others, protein purification, including ultracentrifugation, precipitation and chromatography, as well as protein analysis and determination, including immunohistochemistry, immunofluorescence, ELISA (enzyme linked immunoassay), RIA (radioimmunoassay) or the use of protein microarrays, two-hybrid screening, blotting methods including western blot, one- and two dimensional gelelectrophoresis, isoelectric focusing as well as methods being based on mass spectrometry like MALDI-TOF and the like.
- protein purification including ultracentrifugation, precipitation and chromatography
- protein analysis and determination including immunohistochemistry, immunofluorescence, ELISA (enzyme linked immunoassay), RIA (radioimmunoassay) or the use of protein microarrays, two-hybrid screening, blotting
- marker gene refers to a differentially expressed gene whose expression pattern may be utilized as part of a predictive, prognostic or diagnostic process in malignant neoplasia or cancer evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment or prevention of malignant neoplasia and head and neck, colon or breast cancer in particular.
- a marker gene may also have the characteristics of a target gene.
- immunohistochemistry refers to the process of localizing proteins in cells of a tissue section exploiting the principle of antibodies binding specifically to antigens in biological tissues. Immunohistochemical staining is widely used in the diagnosis and treatment of cancer. Specific molecular markers are characteristic of particular cancer types. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue.
- a “score” within the meaning of the invention shall be understood as a numeric value, which is related to the outcome of a patient's disease and/or the response of a tumor to a specific chemotherapy treatment.
- the numeric value is derived by combining the expression levels of marker genes using prespecified coefficients in a mathematic algorithm.
- the expression levels can be employed as CT or delta-CT values obtained by kinetic RT-PCR, as absolute or relative fluorescence intensity values obtained through microarrays or by any other method useful to quantify absolute or relative RNA levels. Combining these expression levels can be accomplished for example by multiplying each expression level with a defined and specified coefficient and summing up such products to yield a score.
- the score may be also derived from expression levels together with other information, e. g.
- Cut-off values may be applied to distinguish clinical relevant subgroups. Cut-off values for such scores can be determined in the same way as cut-off values for conventional diagnostic markers and are well known to those skilled in the art.
- a useful way of determining such cut-off value is to construct a receiver-operator curve (ROC curve) on the basis of all conceivable cut-off values, determine the single point on the ROC curve with the closest proximity to the upper left corner (0/1) in the ROC plot. Obviously, most of the time cut-off values will be determined by less formalized procedures by choosing the combination of sensitivity and specificity determined by such cutoff value providing the most beneficial medical information to the problem investigated.
- ROC curve receiver-operator curve
- the “response of a tumor to chemotherapy”, within the meaning of the invention, relates to any response of the tumor to cytotoxic chemotherapy, preferably to a change in tumor mass and/or volume after initiation of neoadjuvant chemotherapy and/or prolongation of time to distant metastasis or time to death following neoadjuvant or adjuvant chemotherapy.
- Tumor response may be assessed in a neoadjuvant situation where the size of a tumor after systemic intervention can be compared to the initial size and dimensions as measured by CT, PET, mammogram, ultrasound or palpation, usually recorded as “clinical response” of a patient.
- Response may also be assessed by caliper measurement or pathological examination of the tumor after biopsy or surgical resection.
- neoadjuvant therapy may be recorded in a quantitative fashion like percentage change in tumor volume or in a qualitative fashion like “no change” (NC), “partial remission” (PR), “complete remission” (CR) or other qualitative criteria.
- Assessment of tumor response may be done early after the onset of neoadjuvant therapy e.g. after a few hours, days, weeks or preferably after a few months.
- a typical endpoint for response assessment is upon termination of neoadjuvant chemotherapy or upon surgical removal of residual tumor cells and/or the tumor bed. This is typically three month after initiation of neoadjuvanttherapy.
- Response may also be assessed by comparing time to distant metastasis or death of a patient following neoadjuvant or adjuvant chemotherapy with time to distant metastasis or death of a patient not treated with chemotherapy.
- the term “therapy” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or anti stroma, and/or immune stimulating or suppressive, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermia, and/or hypothermia for cancer therapy.
- the administration of these can be performed in an adjuvant and/or neoadjuvant mode.
- the composition of such “protocol” may vary in the dose of each of the single agents, timeframe of application and frequency of administration within a defined therapy window.
- a “taxane/anthracycline-containing chemotherapy” is a therapy modality comprising the administration of taxane and/or anthracycline and therapeutically effective derivates thereof.
- WO 2008/006517 A2 discloses methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes.
- the set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracyclinecyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.
- taxane based chemotherapy such as e.g. a taxane-anthracyclinecyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-
- WO 2011/121028 A1 relates to a method or predicting an outcome of cancer in a patient suffering from cancer, said method comprising: (a) determining in a biological sample from said patient the expression level of at least one marker gene selected from AKR1C3, MAP4, SPP1, CXCL9, PTGER3, and VEGFC; (b) comparing said expression level to a reference pattern of expression, wherein an increased expression of said at least one marker gene is indicative of said patient having a benefit from microtubule stabilizing agent-based cytotoxic chemotherapy.
- US 2011/306513 A1 relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same.
- a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU
- markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer.
- WO 03/001985 A2 discloses non-invasive methods for detecting, monitoring, staging, and diagnosing malignant melanoma in a skin sample of a subject.
- the methods include analyzing expression in skin sample of one or more melanoma skin markers.
- the melanoma skin markers include IL-1 RI, endothelin-2, ephrin-A5, IGF Binding Protein 7, HLA-AO202 heavy chain, Activin A (beta A subunit), TNF RII, SPC4, and CNTF R alpha.
- the skin sample can include nucleic acids, and can be a human skin sample from a lesion suspected of being melanoma.
- This disclosure focuses on a predictive test that will help the oncologist to identify patients who will have a benefit from inclusion of taxane in a chemotherapy regimen and thus will help to make decisions on therapeutic regimens.
- the biomarker and algorithms were identified in an in-vitro sensitivity study.
- the present invention relates to a method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method comprises the steps of:
- a high expression level of S100P and PCSK6 generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen.
- said expression level is determined as an mRNA level.
- said gene expression level is preferably determined by at least one of the following methods:
- a preferred form is kinetic or quantitative RT-PCR using e.g. commercially available systems such as Taqman, Lightcycler or others.
- the expression level of said at least one marker gene is determined as a pattern of expression relative to at least one reference gene or to a computed average expression value.
- said step of mathematically combining comprises a step of applying an algorithm to values representative of an expression level of a given gene.
- two or more thresholds are determined for said gene expression level or combined score and discriminated into (1) “predicted benefit” and “predicted non-benefit”, (2) “predicted benefit” and “predicted adverse effect”, (3) “predicted benefit”, “predicted indifferent effect” and “predicted adverse effect”, or more risk groups with different probabilities of benefit by applying the threshold on the combined score.
- the invention further relates to a kit for performing a method as described above, said kit comprising a set of oligonucleotides capable of specifically binding sequences or to sequences of fragments of the genes: S100P and PCSK6.
- the invention further relates to a computer program product capable of processing values representative of an expression level of a combination of genes, mathematically combining said values to yield a combined score, wherein said combined score is predicting said benefit from inclusion of taxane in cytotoxic chemotherapy.
- the combined score can be transformed to a given scale in an additional step. Said transformation may be linear or non-linear, continuous or discontinuous, bounded or unbounded, monotonic or non-monotonic.
- Said computer program product may be stored on a data carrier or implemented on a diagnostic system capable of outputting values representative of an expression level of a given gene, such as a real time PCR system.
- the computer program product is stored on a data carrier or running on a computer, operating personal can input the expression values obtained for the expression level of the respective genes.
- the computer program product can then apply an algorithm to produce a combined score indicative of a benefit from taxane-based cytotoxic chemotherapy for a given patient.
- the methods of the present invention have the advantage of providing a reliable prediction of benefit from the inclusion of taxanes in a cytotoxic chemotherapy regimen based on the use of only a small number of genes.
- said cancer is breast cancer.
- the marker genes described in this invention are not breast cancer specific genes, but generally cancer-relevant genes or genes relevant to the therapeutic mechanism of microtubule stabilizing drugs. It can therefore be expected that the methods of the invention are also predictive in other cancers, in which taxane-based therapy is commonly administered, such as lung cancer, headand-neck cancer, ovarian cancer and prostate cancer.
- FIG. 1 Correlation between S100P gene expression levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients.
- FIG. 2 Correlation between PCSK6 gene expression levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients.
- FIG. 3 Correlation between Metagene (mean expression of S100P and PCSK6) RNA levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples.
- An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients.
- FIG. 4 Correlation between S100P/PCSK6 score (non-linear combination of S100P and PCSK6 expression levels) and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients.
- FIG. 5 Platform transfer—S100P: The results from the Affymetrix data (log 2 expression data) in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR, dCt level) and formalin-fixed paraffin-embedded tissue using 56 paired technical samples.
- FIG. 6 Platform transfer—PCSK6: The results from the Affymetrix data (log 2 expression data) in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR, dCt level) and formalin-fixed paraffin-embedded tissue using 56 paired technical samples.
- the methods of the invention are particularly suited for predicting a benefit from inclusion of taxane in a chemotherapy regimen, preferably in breast cancer patients.
- Two predictive marker genes S100P and PCSK6 were identified, whereas a high expression level indicates a benefit from inclusion of taxane in a chemotherapy regimen (FIGS. 1 / 2 ).
- S100P has been described to be associated with paclitaxel resistance/sensitivity in ovarian cancer cell lines. S100P was overexpressed in stable cell lines derived from ovarian cancer cells and silenced using S100Ptargeted siRNA. Both experiments showed that the expression level of S100P contributes to paclitaxel sensitivity (Wang et al., Cancer Lett.; 2008, pp. 277-289; Gao et al., Chin Med J., 2008, pp. 1563-1568; He et al., Oncol Rep., 2008, pp. 325-332).
- the invention comprises the expression analysis of both genes of interest, whereas the expression levels are mathematically combined to yield a score, which is predictive for said benefit of a taxane-based cytotoxic chemotherapy (FIGS. 3 / 4 ).
- In-vitro chemosensitivity assays were carried out using different cytotoxic agents (e. g. Paclitaxel, 5-Fluorouracil, Epirubicin) to determine the response of a tumor towards a specific agent.
- the primary tumors were treated with increased concentration of the respective cytotoxic agent.
- the vitality of the tumor cells was determined using an ATP assay and an area under the dose-response curve (AUC) was determined for every tumor sample and all agents, respectively. An increased AUC indicated a higher sensitivity towards a specific chemotherapeutic agent.
- Sensitivity results from the in-vitro chemosensitivity assays were used as the primary endpoint for the assessment of treatment response.
- the AUC response rates were normalized and the differences between the normalized taxane AUC and the mean AUC of 5-Fluorouracil and Epirubicin were calculated, resulting in a taxane-response score.
- An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients.
- Gene expression levels from the Affymetrix data were correlated to the taxane response score.
- the expression levels from two genes (S100P/PCSK6) were found to be significantly correlated to the taxane-response score ( FIG. 1-4 ).
- Table 1 shows Affymetrix probeset ID and TaqMan design ID mapping of the marker genes of the present invention.
- Table 2 shows full names, Entrez GeneID and chromosomal location of the marker genes of the present invention.
- the results from the Affymetrix data in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR) and formalin-fixed paraffinembedded tissue using 56 paired technical samples.
- the platform transfer was done using Affymetrix microarray data (fresh-frozen tumor samples) and qRTPCR expression data (FFPE samples) from the same technical samples (FIG. 5 / 6 ).
- the method of the invention can be practiced using two technologies: 1.) Isolation of total RNA from fresh or fixed tumor tissue and 2.) Quantitative RT-PCR of the isolated nucleic acids.
- alternative technologies including but not limited to microarray, in particular Affymetrix U-133A arrays, sequencing or by measurement at a protein level.
- RNA species can be isolated from any type of tumor sample, e.g. biopsy samples, smear samples, resected tumor material, fresh frozen tumor tissue or from paraffin embedded and formalin fixed tumor tissue.
- RNA levels of genes coding for the genes S100P and PSCK6 are determined.
- a predictive score is calculated by a mathematical combination, e.g. a linear or non-linear combination (FIGS. 3 / 4 ).
- a high score indicates an increased likelihood of a benefit from inclusion of taxane in a chemotherapy regimen, whereas a low score value indicates a decreased likelihood.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method comprises the steps of: a) determining in a tumor sample from said patient the expression levels of the marker genes S100P and PCSK6, and b) mathematically combining the expression level values of the genes PCSK6 and S100P to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient or c) mathematically combining the expression level value of PCSK6 and S100P with the expression values of other genes to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient.
Description
- The present invention relates to methods, kits and systems for predicting the benefit from inclusion of taxane in a chemotherapy regimen based on the measurements of gene expression levels in tumor samples of breast cancer patients.
- Breast cancer is the most common tumor type and the leading cause of can-cer-related death in women (Jemal et al., CA Cancer J Clin., 2011). Considerable progress has been made in terms of breast cancer diagnosis and treatment in the last years.
- After surgical removal of the primary tumor, breast cancer patients are frequently treated with radiotherapy, hormone therapy and cytotoxic chemotherapy to reduce the risk of recurrence. Today, anthracycline and taxane-based treatment strategies are commonly used in clinical routine, since these regimens have been shown to be superior compared to other standard chemotherapies.
- Several large clinical trials demonstrated that the addition of taxanes to anthracycline-based treatment strategies results in an improved clinical outcome (Martin et al., NEJM, 2005, Gianni, K O, 2009). Although, taxanes are among the most active agents, the absolute benefit of taxane-based treatment is modest (3-5%) and has to be balanced according to serious side-effects.
- To reduce the number of patients suffering from side effects without a clear benefit of the therapy regimen, there is a great need for novel predictive tests to identify a group of patients that can be safely treated with conventional chemotherapy and a subgroup that has a significant benefit of taxane-based treatment.
- Considerable efforts have been made to identify biomarkers that allow a prediction of a specific treatment while minimizing the risk of unnecessary side effects. Ki67—a well-known cell proliferation marker—has been described to predict the benefit from adjuvant taxane-based treatment in the PACS01 trial (Penault-Llorca, JCO, 2008). However, neither the association between Ki67 index and treatment effect nor any other clinicopathological parameter or biomarker predictive for the efficiency of taxanes has been validated so far.
- The most challenging treatment decision in this context concerns ER+/HER2− breast cancer patients, for which classical clinical factors like grading, tumor size or lymph node involvement do not provide a clear answer to the question whether to use chemotherapy or not and what type of treatment therapy is appropriate for the individual patient.
- Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- The term “tumor” as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- The term “cancer” is not limited to any stage, grade, histomorphological feature, aggressivity, or malignancy of an affected tissue or cell aggregation.
- The term “prediction”, as used herein, relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (OAS, overall survival or DFS, disease free survival) of a patient, if the tumor is treated with a given therapy.
- A “benefit” from a given therapy is an improvement in health or wellbeing that can be observed in patients under said therapy, but isn't observed in patients not receiving this therapy. Non-limiting examples commonly used in oncology to gauge a benefit from therapy are survival, disease free survival, metastasis free survival, disappearance of metastasis, tumor regression, and tumor remission.
- A “risk” is understood to be a probability of a subject or a patient to develop or arrive at a certain disease outcome. The term “risk” in the context of the present invention is not meant to carry any positive or negative connotation with regard to a patient's wellbeing but merely refers to a probability or likelihood of an occurrence or development of a given condition.
- The term “node positive”, “diagnosed as node positive”, “node involvement” or “lymph node involvement” means a patient having previously been diagnosed with lymph node metastasis. It shall encompass both draining lymph node, near lymph node, and distant lymph node metastasis. This previous diagnosis itself shall not form part of the inventive method. Rather it is a precondition for selecting patients whose samples may be used for one embodiment of the present invention. This previous diagnosis may have been arrived at by any suitable method known in the art, including, but not limited to lymph node removal and pathological analysis, biopsy analysis, in-vitro analysis of biomarkers indicative for metastasis, imaging methods (e.g. computed tomography, X-ray, magnetic resonance imaging, ultrasound), and intraoperative findings.
- In the context of the present invention a “biological sample” is a sample which is derived from or has been in contact with a biological organism. Examples for biological samples are: cells, tissue, body fluids, lavage fluid, smear samples, biopsy specimens, blood, urine, saliva, sputum, plasma, serum, cell culture supernatant, and others. A “tumor sample” is a biological sample containing tumor cells, no matter if intact or degraded.
- A “gene” is a set of segments of nucleic acid that contains the information necessary to produce a functional RNA product. A “gene product” is a biological molecule produced through transcription or expression of a gene, e.g. an mRNA or the translated protein.
- An “mRNA” is the transcribed product of a gene or a part of a gene and shall have the ordinary meaning understood by a person skilled in the art. A “molecule derived from an mRNA” is a molecule which is chemically or enzymatically obtained from an mRNA template, such as cDNA.
- The term “expression level” refers to a determined level of gene expression. This may be a determined level of gene expression as an absolute value or compared to a reference gene (e.g. a housekeeping gene) or to a computed average expression value (e.g. in DNA chip analysis) or to another informative gene without the use of a reference sample. The expression level of a gene may be measured directly, e.g. by obtaining a signal wherein the signal strength is correlated to the amount of mRNA transcripts of that gene or it may be obtained indirectly at a DNA or protein level, e.g. by immunohistochemistry, CISH, ELISA or RIA methods. The expression level may also be obtained by way of a competitive reaction to a reference sample. An expression value which is determined by measuring some physical parameter in an assay, e.g. fluorescence emission, may be assigned a numerical value which may be used for further processing of information.
- A “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels. In a preferred embodiment of the invention, a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy individuals, diseased individuals, or diseased individuals having received a particular type of therapy, serving as a reference group.
- As all measurement results also gene expressions values or combined scores, consisting of a mathematical combination of one or more gene expression values, require to be compared to a “reference-value” to get a meaning in a clinical context. As such an expression value or a combined score exceeding such a “reference-value”, by way of example may mean an improved or worsened likelihood of survival for a patient. Such “reference-value” can be a numerical cutoff value, it can be derived from a reference measurement of one or more other genes in the same sample, or one or more other genes and/or the same gene in one other sample or in a plurality of other samples. This is how “reference-value” within the meaning of this invention should be understood.
- The term “mathematically combining expression levels”, within the meaning of the invention shall be understood as deriving a numeric value from a determined expression level of a gene and applying an algorithm to obtain a combined numerical value or combined score.
- An “algorithm” is a process that performs some sequence of operations to process an information.
- The term “cytotoxic treatment” or “cytotoxic chemotherapy” refers to various treatment modalities affecting cell proliferation and/or survival. The treatment may include administration of alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumour agents, including monoclonal antibodies and kinase inhibitors. In particular, the cytotoxic treatment may relate to a treatment comprising microtubulestabilizing drugs such as taxanes or epothilones.
- The term “neoadjuvant chemotherapy” relates to a preoperative therapy regimen consisting of a panel of hormonal, chemotherapeutic and/or antibody agents, which is aimed to shrink the primary tumor, thereby rendering local therapy (surgery or radiotherapy) less destructive or more effective, enabling breast conserving surgery and evaluation of responsiveness of tumor sensitivity towards specific agents in vivo.
- A “microtubule stabilizing agent-based” treatment or therapy is a treatment or therapy comprising taxol or therapeutically effective derivatives thereof, epothilones or therapeutically effective derivatives thereof or other microtubule stabilizing cytotoxic drugs.
- A “taxane-based” treatment or therapy is a treatment or therapy comprising taxol or therapeutically effective derivatives thereof. The principal mechanism of the taxane class of drugs is the disruption of microtubule function.
- The term “hybridization-based method”, as used herein, refers to methods imparting a process of combining complementary, single-stranded nucleic acids or nucleotide analogues into a single double stranded molecule. Nucleotides or nucleotide analogues will bind to their complement under normal conditions, so two perfectly complementary strands will bind to each other readily. In bioanalytics, very often labeled, single stranded probes are in order to find complementary target sequences. If such sequences exist in the sample, the probes will hybridize to said sequences which can then be detected due to the label. Other hybridization based methods comprise microarray and/or biochip methods. Therein, probes are immobilized on a solid phase, which is then exposed to a sample. If complementary nucleic acids exist in the sample, these will hybridize to the probes and can thus be detected. These approaches are also known as “array based methods”. Yet another hybridization based method is PCR, which is described above. When it comes to the determination of expression levels, hybridization based methods may for example be used to determine the amount of mRNA for a given gene.
- An oligonucleotide capable of specifically binding sequences a gene or fragments thereof relates to an oligonucleotide which specifically hybridizes to a gene or gene product, such as the gene's mRNA or cDNA or to a fragment thereof. To specifically detect the gene or gene product, it is not necessary to detect the entire gene sequence. A fragment of about 20-150 bases will contain enough sequence specific information to allow specific hybridization.
- The term “a PCR based method” as used herein refers to methods comprising a polymerase chain reaction (PCR). This is a method of exponentially amplifying nucleic acids, e.g. DNA by enzymatic replication in vitro. As PCR is an in vitro technique, it can be performed without restrictions on the form of DNA, and it can be extensively modified to perform a wide array of genetic manipulations. When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers. This approach is commonly known as reverse transcriptase PCR (rtPCR).Moreover, PCR-based methods comprise e.g. real time PCR, and, particularly suited for the analysis of expression levels, kinetic or quantitative PCR (qPCR). The term “Quantitative PCR” (qPCR)” refers to any type of a PCR method which allows the quantification of the template in a sample. Quantitative real-time PCR comprise different techniques of performance or product detection as for example the TaqMan technique or the LightCycler technique. The TaqMan technique, for examples, uses a dual-labelled fluorogenic probe. The TaqMan real-time PCR measures accumulation of a product via the fluorophore during the exponential stages of the PCR, rather than at the end point as in conventional PCR. The exponential increase of the product is used to determine the threshold cycle, CT, i.e. the number of PCR cycles at which a significant exponential increase in fluorescence is detected, and which is directly correlated with the number of copies of DNA template present in the reaction. The set up of the reaction is very similar to a conventional PCR, but is carried out in a real-time thermal cycler that allows measurement of fluorescent molecules in the PCR tubes. Different from regular PCR, in TaqMan real-time PCR a probe is added to the reaction, i.e., a single-stranded oligonucleotide complementary to a segment of 20-60 nucleotides within the DNA template and located between the two primers. A fluorescent reporter or fluorophore (e.g., 6-carboxyfluorescein, acronym: FAM, or tetrachlorofluorescein, acronym: TET) and quencher (e.g., tetramethylrhodamine, acronym: TAMRA, of dihydrocyclopyrroloindole tripeptide “minor groove binder”, acronym: MGB) are covalently attached to the 5′ and 3′ ends of the probe, respectively[2]. The close proximity between fluorophore and quencher attached to the probe inhibits fluorescence from the fluorophore. During PCR, as DNA synthesis commences, the 5′ to 3′ exonuclease activity of the Taq polymerase degrades that proportion of the probe that has annealed to the template (Hence its name: Taq polymerase+TacMan). Degradation of the probe releases the fluorophore from it and breaks the close proximity to the quencher, thus relieving the quenching effect and allowing fluorescence of the fluorophore. Hence, fluorescence detected in the real-time PCR thermal cycler is directly proportional to the fluorophore released and the amount of DNA template present in the PCR.
- By “array” or “matrix” an arrangement of addressable locations or “addresses” on a device is meant. The locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats. The number of locations can range from several to at millions. Most importantly, each location represents a totally independent reaction site. Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays. A “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, nucleotide analogues, polynucleotides, polymers of nucleotide analogues, morpholinos or larger portions of genes. The nucleic acid and/or analogue on the array is preferably single stranded. Arrays wherein the probes are oligonucleotides are referred to as “oligo-nucleotide arrays” or “oligo-nucleotide chips.” A “microarray,” herein also refers to a “biochip” or “biological chip”, an array of regions having a density of discrete regions of at least about 100/cm2, and preferably at least about 1000/cm2.
- The term “therapy modality”, “therapy mode”, “regimen” or “chemo regimen” as well as “therapy regimen” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or immune stimulating, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermic, and/or hypothermia for cancer therapy. The administration of these can be performed in an adjuvant and/or neoadjuvant mode. The composition of such “protocol” may vary in the dose of the single agent, timeframe of application and frequency of administration within a defined therapy window. Currently various combinations of various drugs and/or physical methods, and various schedules are under investigation.
- The term “measurement at a protein level”, as used herein, refers to methods which allow for the quantitative and/or qualitative determination of one or more proteins in a sample. These methods include, among others, protein purification, including ultracentrifugation, precipitation and chromatography, as well as protein analysis and determination, including immunohistochemistry, immunofluorescence, ELISA (enzyme linked immunoassay), RIA (radioimmunoassay) or the use of protein microarrays, two-hybrid screening, blotting methods including western blot, one- and two dimensional gelelectrophoresis, isoelectric focusing as well as methods being based on mass spectrometry like MALDI-TOF and the like.
- The term “marker gene” as used herein, refers to a differentially expressed gene whose expression pattern may be utilized as part of a predictive, prognostic or diagnostic process in malignant neoplasia or cancer evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment or prevention of malignant neoplasia and head and neck, colon or breast cancer in particular. A marker gene may also have the characteristics of a target gene.
- The term “immunohistochemistry” or IHC refers to the process of localizing proteins in cells of a tissue section exploiting the principle of antibodies binding specifically to antigens in biological tissues. Immunohistochemical staining is widely used in the diagnosis and treatment of cancer. Specific molecular markers are characteristic of particular cancer types. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue.
- A “score” within the meaning of the invention shall be understood as a numeric value, which is related to the outcome of a patient's disease and/or the response of a tumor to a specific chemotherapy treatment. The numeric value is derived by combining the expression levels of marker genes using prespecified coefficients in a mathematic algorithm. The expression levels can be employed as CT or delta-CT values obtained by kinetic RT-PCR, as absolute or relative fluorescence intensity values obtained through microarrays or by any other method useful to quantify absolute or relative RNA levels. Combining these expression levels can be accomplished for example by multiplying each expression level with a defined and specified coefficient and summing up such products to yield a score. The score may be also derived from expression levels together with other information, e. g. clinical data like tumor size, lymph node status or tumor grading as such variables can also be coded as numbers in an equation. The score may be used on a continuous scale to predict the response of a tumor to a specific chemotherapy and/or the outcome of a patient's disease. Cut-off values may be applied to distinguish clinical relevant subgroups. Cut-off values for such scores can be determined in the same way as cut-off values for conventional diagnostic markers and are well known to those skilled in the art. A useful way of determining such cut-off value is to construct a receiver-operator curve (ROC curve) on the basis of all conceivable cut-off values, determine the single point on the ROC curve with the closest proximity to the upper left corner (0/1) in the ROC plot. Obviously, most of the time cut-off values will be determined by less formalized procedures by choosing the combination of sensitivity and specificity determined by such cutoff value providing the most beneficial medical information to the problem investigated.
- The “response of a tumor to chemotherapy”, within the meaning of the invention, relates to any response of the tumor to cytotoxic chemotherapy, preferably to a change in tumor mass and/or volume after initiation of neoadjuvant chemotherapy and/or prolongation of time to distant metastasis or time to death following neoadjuvant or adjuvant chemotherapy. Tumor response may be assessed in a neoadjuvant situation where the size of a tumor after systemic intervention can be compared to the initial size and dimensions as measured by CT, PET, mammogram, ultrasound or palpation, usually recorded as “clinical response” of a patient. Response may also be assessed by caliper measurement or pathological examination of the tumor after biopsy or surgical resection. Response may be recorded in a quantitative fashion like percentage change in tumor volume or in a qualitative fashion like “no change” (NC), “partial remission” (PR), “complete remission” (CR) or other qualitative criteria. Assessment of tumor response may be done early after the onset of neoadjuvant therapy e.g. after a few hours, days, weeks or preferably after a few months. A typical endpoint for response assessment is upon termination of neoadjuvant chemotherapy or upon surgical removal of residual tumor cells and/or the tumor bed. This is typically three month after initiation of neoadjuvanttherapy. Response may also be assessed by comparing time to distant metastasis or death of a patient following neoadjuvant or adjuvant chemotherapy with time to distant metastasis or death of a patient not treated with chemotherapy.
- The term “therapy” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or anti stroma, and/or immune stimulating or suppressive, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermia, and/or hypothermia for cancer therapy. The administration of these can be performed in an adjuvant and/or neoadjuvant mode. The composition of such “protocol” may vary in the dose of each of the single agents, timeframe of application and frequency of administration within a defined therapy window. Currently various combinations of various drugs and/or physical methods, and various schedules are under investigation. A “taxane/anthracycline-containing chemotherapy” is a therapy modality comprising the administration of taxane and/or anthracycline and therapeutically effective derivates thereof.
- WO 2008/006517 A2 discloses methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracyclinecyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.
- WO 2011/121028 A1 relates to a method or predicting an outcome of cancer in a patient suffering from cancer, said method comprising: (a) determining in a biological sample from said patient the expression level of at least one marker gene selected from AKR1C3, MAP4, SPP1, CXCL9, PTGER3, and VEGFC; (b) comparing said expression level to a reference pattern of expression, wherein an increased expression of said at least one marker gene is indicative of said patient having a benefit from microtubule stabilizing agent-based cytotoxic chemotherapy.
- US 2011/306513 A1 relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer. The markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer.
- WO 03/001985 A2 discloses non-invasive methods for detecting, monitoring, staging, and diagnosing malignant melanoma in a skin sample of a subject. The methods include analyzing expression in skin sample of one or more melanoma skin markers. The melanoma skin markers include IL-1 RI, endothelin-2, ephrin-A5,
IGF Binding Protein 7, HLA-AO202 heavy chain, Activin A (beta A subunit), TNF RII, SPC4, and CNTF R alpha. The skin sample can include nucleic acids, and can be a human skin sample from a lesion suspected of being melanoma. - Yuexin Liu, et al., concludes that a gene signature discovered on a large data set provides robustness in accurately predicting chemotherapy response in serous ovarian carcinoma. The combination of the molecular and morphologic signatures yields a new understanding of potential mechanisms involved in drug resistance (Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma, DOI: 10.1371/journal.pone.0036383).
- It is an objective of the invention to provide a method for identification of patients, particularly breast cancer patients, who have a benefit from receiving taxanes as a part of their chemotherapy.
- It is another object of the present invention to avoid unnecessary side-effects of adjuvant and/or neo-adjuvant taxane-based chemotherapy.
- It is another object of the present invention to offer a more robust and specific diagnostic assay system for clinical routine fixed tissue samples to select individualized treatment modalities.
- This disclosure focuses on a predictive test that will help the oncologist to identify patients who will have a benefit from inclusion of taxane in a chemotherapy regimen and thus will help to make decisions on therapeutic regimens. The biomarker and algorithms were identified in an in-vitro sensitivity study.
- The present invention relates to a method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method comprises the steps of:
-
- a) determining in a tumor sample from said patient the expression levels of the marker genes S100P and PCSK6,
- and
- b) mathematically combining the expression level values of the genes PCSK6 and S100P to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient
- or
- c) mathematically combining the expression level values of PCSK6 and
- a) determining in a tumor sample from said patient the expression levels of the marker genes S100P and PCSK6,
- S100P with the expression values of other genes to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient.
- According to an aspect of the invention a high expression level of S100P and PCSK6 generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen.
- According to an aspect of the invention there is provided a method as described above, wherein said expression level is determined as an mRNA level. According to an aspect of the invention there is provided a method as described above, wherein said gene expression level is preferably determined by at least one of the following methods:
-
- a PCR based method,
- a micorarray based method,
- a hybridization based method,
- a sequencing and/or
- next generation sequencing approach.
- A preferred form is kinetic or quantitative RT-PCR using e.g. commercially available systems such as Taqman, Lightcycler or others.
- According to an aspect of the invention there is provided a method as described above, wherein said determination of expression levels is in a formalin-fixed paraffin-embedded tumor sample or in a fresh-frozen tumor sample.
- According to an aspect of the invention there is provided a method as described above, wherein the expression level of said at least one marker gene is determined as a pattern of expression relative to at least one reference gene or to a computed average expression value.
- According to an aspect of the invention there is provided a method as described above, wherein said step of mathematically combining comprises a step of applying an algorithm to values representative of an expression level of a given gene.
- According to an aspect of the invention there is provided a method as described above, wherein said algorithm is a mathematical combination of said values representative of an expression level of a given gene.
- According to an aspect of the invention there is provided a method as described above, wherein a value for a representative of an expression level of a given gene is multiplied with a coefficient.
- According to an aspect of the invention one, two or more thresholds are determined for said gene expression level or combined score and discriminated into (1) “predicted benefit” and “predicted non-benefit”, (2) “predicted benefit” and “predicted adverse effect”, (3) “predicted benefit”, “predicted indifferent effect” and “predicted adverse effect”, or more risk groups with different probabilities of benefit by applying the threshold on the combined score.
- According to an aspect of the invention there is provided a method as described above, wherein information regarding clinical parameters of the patient is processed in the step of mathematically combining expression level values for the genes to yield a combined score.
- The invention further relates to a kit for performing a method as described above, said kit comprising a set of oligonucleotides capable of specifically binding sequences or to sequences of fragments of the genes: S100P and PCSK6.
- The invention further relates to a computer program product capable of processing values representative of an expression level of a combination of genes, mathematically combining said values to yield a combined score, wherein said combined score is predicting said benefit from inclusion of taxane in cytotoxic chemotherapy. The combined score can be transformed to a given scale in an additional step. Said transformation may be linear or non-linear, continuous or discontinuous, bounded or unbounded, monotonic or non-monotonic.
- Said computer program product may be stored on a data carrier or implemented on a diagnostic system capable of outputting values representative of an expression level of a given gene, such as a real time PCR system.
- If the computer program product is stored on a data carrier or running on a computer, operating personal can input the expression values obtained for the expression level of the respective genes. The computer program product can then apply an algorithm to produce a combined score indicative of a benefit from taxane-based cytotoxic chemotherapy for a given patient.
- The methods of the present invention have the advantage of providing a reliable prediction of benefit from the inclusion of taxanes in a cytotoxic chemotherapy regimen based on the use of only a small number of genes.
- According to an aspect of the invention said cancer is breast cancer. The marker genes described in this invention are not breast cancer specific genes, but generally cancer-relevant genes or genes relevant to the therapeutic mechanism of microtubule stabilizing drugs. It can therefore be expected that the methods of the invention are also predictive in other cancers, in which taxane-based therapy is commonly administered, such as lung cancer, headand-neck cancer, ovarian cancer and prostate cancer.
-
FIG. 1 : Correlation between S100P gene expression levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients. -
FIG. 2 : Correlation between PCSK6 gene expression levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients. -
FIG. 3 : Correlation between Metagene (mean expression of S100P and PCSK6) RNA levels and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients. -
FIG. 4 : Correlation between S100P/PCSK6 score (non-linear combination of S100P and PCSK6 expression levels) and taxane response scores (derived from the in-vitro chemosensitivity data) in all 29 breast cancer samples An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients. -
FIG. 5 : Platform transfer—S100P: The results from the Affymetrix data (log 2 expression data) in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR, dCt level) and formalin-fixed paraffin-embedded tissue using 56 paired technical samples. -
FIG. 6 : Platform transfer—PCSK6: The results from the Affymetrix data (log 2 expression data) in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR, dCt level) and formalin-fixed paraffin-embedded tissue using 56 paired technical samples. - Additional details, features, characteristics and advantages of the object of the invention are disclosed in the subclaims, and the following description of the respective figures and examples. However, these drawings should by no means be understood as to limit the scope of the invention.
- The methods of the invention are particularly suited for predicting a benefit from inclusion of taxane in a chemotherapy regimen, preferably in breast cancer patients. Two predictive marker genes (S100P and PCSK6) were identified, whereas a high expression level indicates a benefit from inclusion of taxane in a chemotherapy regimen (FIGS. 1/2).
- S100P has been described to be associated with paclitaxel resistance/sensitivity in ovarian cancer cell lines. S100P was overexpressed in stable cell lines derived from ovarian cancer cells and silenced using S100Ptargeted siRNA. Both experiments showed that the expression level of S100P contributes to paclitaxel sensitivity (Wang et al., Cancer Lett.; 2008, pp. 277-289; Gao et al., Chin Med J., 2008, pp. 1563-1568; He et al., Oncol Rep., 2008, pp. 325-332).
- Villeneuve and colleagues carried out a microarray screening to compare the gene expression profiles between wild-type and paclitaxel-resistant breast cancer cell lines. Several deregulated genes were identified and S100P was among those genes that showed a decreased expression level in paclitaxelresistant cell lines. (Villeneuve et al., Breast Cancer Res Treat., 2006, pp. 17-39).
- The stated prior art does not necessarily suggest that S100P is a predictive marker for breast cancer patients, since gene expression profiles and resistance mechanisms can be considerably different between cell lines (“in-vitro”) and the primary tumor of cancer patients (“in-vivo”).
- Here, we show for the first time that S100P as well as PCSK6 predict taxane efficacy in breast cancer patients (“in-vivo”). The combination of PCSK6 and S100P gene expression levels improves the predictive performance in comparison to the single markers (PCSK6 or S100P) alone (
FIG. 1-4 ). - Therefore, the invention comprises the expression analysis of both genes of interest, whereas the expression levels are mathematically combined to yield a score, which is predictive for said benefit of a taxane-based cytotoxic chemotherapy (FIGS. 3/4).
- The genes and the algorithms were identified in breast cancer patients. RNA was extracted and used for gene expression profiling (Affymetrix HG-U133A microarrays). Microarray cel files were MAS5 normalized with a global scaling procedure and a target intensity of 500. In-vitro chemosensitivity assays were carried out using different cytotoxic agents (e. g. Paclitaxel, 5-Fluorouracil, Epirubicin) to determine the response of a tumor towards a specific agent. The primary tumors were treated with increased concentration of the respective cytotoxic agent. The vitality of the tumor cells was determined using an ATP assay and an area under the dose-response curve (AUC) was determined for every tumor sample and all agents, respectively. An increased AUC indicated a higher sensitivity towards a specific chemotherapeutic agent.
- Sensitivity results from the in-vitro chemosensitivity assays were used as the primary endpoint for the assessment of treatment response. The AUC response rates were normalized and the differences between the normalized taxane AUC and the mean AUC of 5-Fluorouracil and Epirubicin were calculated, resulting in a taxane-response score. An increased taxane response score is associated with a higher likelihood of a higher benefit from a taxane in comparison to 5-Fluorouracil and/or Epirubicin in breast cancer patients. Gene expression levels from the Affymetrix data were correlated to the taxane response score. The expression levels from two genes (S100P/PCSK6) were found to be significantly correlated to the taxane-response score (
FIG. 1-4 ). - Table 1, below, shows Affymetrix probeset ID and TaqMan design ID mapping of the marker genes of the present invention.
-
Gene Design ID Probeset ID S100P SVD0018 204351_at PCSK6 SVD0016 207414_s_at - Table 2, below, shows full names, Entrez GeneID and chromosomal location of the marker genes of the present invention.
-
Official Symbol Official Full Name Entrez Location S100P S100 calcium binding protein P 6286 4p16 PCSK6 proprotein convertase subtilisin/ 5046 15q26.3 kexin type 6 - The results from the Affymetrix data in fresh-frozen tumor samples were transferred to a diagnostic platform (qRT-PCR) and formalin-fixed paraffinembedded tissue using 56 paired technical samples. The platform transfer was done using Affymetrix microarray data (fresh-frozen tumor samples) and qRTPCR expression data (FFPE samples) from the same technical samples (FIG. 5/6).
-
TABLE 3 qRT-PCR primer and probe sequences Gene Seq Id symbol Primer- ID Probe 1 S100P SVD0018 CTGCAATCACGTCTGCCTGTCACAAGT 2 PCSK6 SVD0016 CTGCTCCCCTGTTTGACGACAGTGC Gene Seq Id symbol Primer- ID Forward Primer 1 S100P SVD0018 TTCAGTGAGTTCATCGTGTTCGT 2 PCSK6 SVD0016 TTTCGACCTCGTCTTTCTCCAT Gene Seq Id symbol Primer- ID Reverse Primer 1 S100P SVD0018 CATCATTTGAGTCCTGCCTTCTC 2 PCSK6 SVD0016 TCTCTCCAGCTCACAGGTGACA - Herein disclosed are unique combinations of two marker genes which can be combined into an algorithm for the here presented new predictive test. Technically, the method of the invention can be practiced using two technologies: 1.) Isolation of total RNA from fresh or fixed tumor tissue and 2.) Quantitative RT-PCR of the isolated nucleic acids. Alternatively, it is contemplated to measure expression levels using alternative technologies, including but not limited to microarray, in particular Affymetrix U-133A arrays, sequencing or by measurement at a protein level.
- The methods of the invention are based on quantitative determination of RNA species isolated from the tumor in order to obtain expression values and subsequent bioinformatics analysis of said determined expression values. RNA species can be isolated from any type of tumor sample, e.g. biopsy samples, smear samples, resected tumor material, fresh frozen tumor tissue or from paraffin embedded and formalin fixed tumor tissue. First, RNA levels of genes coding for the genes S100P and PSCK6 are determined. Based on these expression values a predictive score is calculated by a mathematical combination, e.g. a linear or non-linear combination (FIGS. 3/4). A high score indicates an increased likelihood of a benefit from inclusion of taxane in a chemotherapy regimen, whereas a low score value indicates a decreased likelihood.
Claims (13)
1. A method for predicting a benefit from inclusion of taxane in a chemotherapy regimen, including adjuvant and/or neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of:
a) determining in a tumor sample from said patient the expression levels of the marker genes S100P and PCSK6,
and
b) mathematically combining the expression level values of the genes PCSK6 and S100P to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient
or
c) mathematically combining the expression level values of PCSK6 and S100P with the expression values of other genes to yield a combined score and comparing said combined score to a reference-value, including a cutoff, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen of said patient.
2. The method of claim 1 , wherein said expression level is determined as a non-protein such as a gene expression level.
3. The method of claim 1 , wherein said expression level is determined by at least one of the following methods:
a PCR based method,
a microarray based method,
a hybridization based method,
a sequencing and/or
next generation sequencing approach.
4. The method of claim 1 , wherein said determination of expression levels is in a formalin-fixed paraffin-embedded tumor sample or in a fresh-frozen tumor sample.
5. The method of claim 1 , wherein the expression levels are determined as a pattern of expression relative to at least one reference gene or to a computed average expression value.
6. The method of claim 1 , wherein said step of mathematically combining the expression level values comprises a step of applying an algorithm to values representative of an expression level of S100P and PCSK6.
7. The method of claim 6 , wherein said algorithm is a linear combination of said values representative of an expression level of S100P and PCSK6.
8. The method of claim 6 , wherein a value for a representative of an expression level of a given gene is multiplied with a coefficient.
9. The method of any one of the foregoing claims claim 1 , wherein one, two or more thresholds are determined for said combined score and discriminated groups by applying the threshold on the combined score.
10. The method of claim 1 , wherein one, two or more thresholds are determined for said combined score and discriminated into (1) “predicted benefit” and “predicted non-benefit”, (2) “predicted benefit” and “predicted adverse effect”, (3) “predicted benefit”, “predicted indifferent effect” and “predicted adverse effect”, or more risk groups with different probabilities of benefit by applying the threshold on the combined score.
11. The method of claim 1 ,
wherein a high combined score is indicative of a benefit from taxane-based treatment.
12. The method of claim 1 ,
wherein information regarding clinical parameters of the patient is processed in the step of mathematically combining expression level values for the genes to yield a combined score.
13. A kit for performing the method of claim 1 , said kit comprising a set of oligonucleotides capable of specifically binding sequences or to sequences of fragments of the genes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13153755.7 | 2013-02-01 | ||
EP13153755 | 2013-02-01 | ||
EP13157350 | 2013-03-01 | ||
EP13157350.3 | 2013-03-01 | ||
PCT/EP2014/051937 WO2014118333A1 (en) | 2013-02-01 | 2014-01-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/051937 A-371-Of-International WO2014118333A1 (en) | 2013-02-01 | 2014-01-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/799,699 Continuation US10301685B2 (en) | 2013-02-01 | 2017-10-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150376714A1 true US20150376714A1 (en) | 2015-12-31 |
Family
ID=50115823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/765,294 Abandoned US20150376714A1 (en) | 2013-02-01 | 2014-01-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
US15/799,699 Expired - Fee Related US10301685B2 (en) | 2013-02-01 | 2017-10-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/799,699 Expired - Fee Related US10301685B2 (en) | 2013-02-01 | 2017-10-31 | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
Country Status (6)
Country | Link |
---|---|
US (2) | US20150376714A1 (en) |
EP (1) | EP2951317B1 (en) |
DK (1) | DK2951317T3 (en) |
ES (1) | ES2654469T3 (en) |
HK (1) | HK1217355A1 (en) |
WO (1) | WO2014118333A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11049238B2 (en) * | 2015-06-22 | 2021-06-29 | Sunnybrook Research Institute | Systems and methods for prediction of tumor response to chemotherapy using pre-treatment quantitative ultrasound parameters |
US11497476B2 (en) * | 2015-06-22 | 2022-11-15 | Sunnybrook Research Institute | Systems and methods for prediction of tumor treatment response to using texture derivatives computed from quantitative ultrasound parameters |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3105344A1 (en) * | 2014-02-12 | 2016-12-21 | Myriad Genetics, Inc. | Method for predicting the response and survival from chemotherapy in patients with breast cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065084A1 (en) * | 2009-04-17 | 2012-03-15 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
US20120142624A1 (en) * | 2009-05-22 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy |
US20140349878A1 (en) * | 2011-11-28 | 2014-11-27 | National Research Council Of Canada | Paclitaxel response markers for cancer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
JP4277452B2 (en) | 2000-02-25 | 2009-06-10 | ソニー株式会社 | Recording device, playback device |
AU2002346008A1 (en) | 2001-06-28 | 2003-03-03 | Dermtech International | Method for detection of melanoma |
US20040002067A1 (en) | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
ATE550440T1 (en) | 2004-11-05 | 2012-04-15 | Genomic Health Inc | MOLECULAR INDICATORS FOR BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE |
CA2596640A1 (en) | 2005-02-04 | 2006-08-10 | Rosetta Inpharmatics Llc | Methods of predicting chemotherapy responsiveness in breast cancer patients |
CN101356532B (en) | 2005-05-13 | 2012-08-01 | 布鲁塞尔自由大学 | Gene-based algorithmic cancer prognosis |
EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
GB0512299D0 (en) | 2005-06-16 | 2005-07-27 | Bayer Healthcare Ag | Diagnosis prognosis and prediction of recurrence of breast cancer |
US20070134688A1 (en) | 2005-09-09 | 2007-06-14 | The Board Of Regents Of The University Of Texas System | Calculated index of genomic expression of estrogen receptor (er) and er-related genes |
WO2008006517A2 (en) | 2006-07-13 | 2008-01-17 | Siemens Healthcare Diagnostics Gmbh | Prediction of breast cancer response to taxane-based chemotherapy |
EP2061885A4 (en) | 2006-09-15 | 2011-03-09 | Univ Mcgill | Stroma derived predictor of breast cancer |
WO2008070571A2 (en) | 2006-12-01 | 2008-06-12 | The Regents Of The University Of California | Vesicles of self-assembling block copolymers and methods for making and using the same |
RU2473555C2 (en) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | New method for functional analysis of body of experimental data and gene groups identified from said data |
EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
EP2036988A1 (en) | 2007-09-12 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent |
WO2009095319A1 (en) | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
WO2009132928A2 (en) | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
US20110166838A1 (en) | 2008-06-16 | 2011-07-07 | Sividon Diagnostics | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
EP2304630A1 (en) | 2008-06-16 | 2011-04-06 | Sividon Diagnostics GmbH | Molecular markers for cancer prognosis |
EP2163649A1 (en) | 2008-09-11 | 2010-03-17 | Fédération Nationale des Centres de Lutte Contre le Cancer | Molecular classifier for evaluating the risk of metastasic relapse in breast cancer |
KR101192297B1 (en) | 2008-12-10 | 2012-10-17 | 한국생명공학연구원 | Novel Biomarkers Indicative of Liver Cancer and Their Uses |
WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
WO2011121028A1 (en) | 2010-03-30 | 2011-10-06 | Siemens Healthcare Diagnostics Inc. | Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer |
PL2845911T3 (en) | 2010-03-31 | 2017-01-31 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment |
WO2012153187A2 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
EP2737081B1 (en) | 2011-07-28 | 2016-09-28 | Sividon Diagnostics GmbH | Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer |
EP3105344A1 (en) | 2014-02-12 | 2016-12-21 | Myriad Genetics, Inc. | Method for predicting the response and survival from chemotherapy in patients with breast cancer |
-
2014
- 2014-01-31 ES ES14705056.1T patent/ES2654469T3/en active Active
- 2014-01-31 DK DK14705056.1T patent/DK2951317T3/en active
- 2014-01-31 EP EP14705056.1A patent/EP2951317B1/en not_active Not-in-force
- 2014-01-31 WO PCT/EP2014/051937 patent/WO2014118333A1/en active Application Filing
- 2014-01-31 US US14/765,294 patent/US20150376714A1/en not_active Abandoned
-
2016
- 2016-05-11 HK HK16105350.5A patent/HK1217355A1/en unknown
-
2017
- 2017-10-31 US US15/799,699 patent/US10301685B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065084A1 (en) * | 2009-04-17 | 2012-03-15 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
US20120142624A1 (en) * | 2009-05-22 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy |
US20140349878A1 (en) * | 2011-11-28 | 2014-11-27 | National Research Council Of Canada | Paclitaxel response markers for cancer |
Non-Patent Citations (1)
Title |
---|
Rathnagiriswaran et al. A population-based gene signature is predictive of breast cancer survival and chemoresponse. March 2010. Int. J. Oncol. Vol. 36, No. 3, page 607-616. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11049238B2 (en) * | 2015-06-22 | 2021-06-29 | Sunnybrook Research Institute | Systems and methods for prediction of tumor response to chemotherapy using pre-treatment quantitative ultrasound parameters |
US11497476B2 (en) * | 2015-06-22 | 2022-11-15 | Sunnybrook Research Institute | Systems and methods for prediction of tumor treatment response to using texture derivatives computed from quantitative ultrasound parameters |
Also Published As
Publication number | Publication date |
---|---|
EP2951317A1 (en) | 2015-12-09 |
US20180135133A1 (en) | 2018-05-17 |
HK1217355A1 (en) | 2017-01-06 |
DK2951317T3 (en) | 2018-01-15 |
EP2951317B1 (en) | 2017-10-11 |
US10301685B2 (en) | 2019-05-28 |
WO2014118333A1 (en) | 2014-08-07 |
ES2654469T3 (en) | 2018-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220307090A1 (en) | Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer | |
KR101437718B1 (en) | Markers for predicting gastric cancer prognostication and Method for predicting gastric cancer prognostication using the same | |
JP5940517B2 (en) | Methods for predicting breast cancer recurrence under endocrine therapy | |
US20100216131A1 (en) | Gene expression profiling of esophageal carcinomas | |
EP2390370B1 (en) | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent | |
WO2008070301A9 (en) | Predicting lung cancer survival using gene expression | |
WO2012007545A1 (en) | Methods and kits for the diagnosis of prostate cancer | |
CA2504403A1 (en) | Prognostic for hematological malignancy | |
US20180230545A1 (en) | Method for the prediction of progression of bladder cancer | |
US10301685B2 (en) | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer | |
US20160348183A1 (en) | Method for predicting the response and survival from chemotherapy in patients with breast cancer | |
EP2553119B1 (en) | Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer | |
JP7016466B2 (en) | Methods for assessing the effectiveness of chemoradiation therapy for squamous cell carcinoma | |
US20230116885A1 (en) | Method of using biomarkers and clinical variables for predicting chemotherapy benefit | |
Ellakwa et al. | Target genes expression biomarkers in Egyptian bladder cancer patients | |
EP4379064A1 (en) | Diagnostic methods and diagnostic assay comprising detection of lncrnas | |
EP3325643B1 (en) | Methods and means for dysplasia analysis | |
US20150329914A1 (en) | Predictive biomarkers for pre-malignant breast lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SIVIDON DIAGNOSTICS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRASE, JAN CHRISTOPH;KRONENWETT, RALF;FISCH, KARIN;AND OTHERS;SIGNING DATES FROM 20160122 TO 20160216;REEL/FRAME:038259/0250 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MYRIAD INTERNATIONAL GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SIVIDON DIAGNOSTICS GMBH;REEL/FRAME:066385/0225 Effective date: 20180209 |